This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Lindsell is professor and cochief of biostatistics and bioinformatics, director of data science and biostatistics at the Duke ClinicalResearch Institute, and director of biostatistics and bioinformatics at the Duke Clinical and Translational Science Instituteall at Duke University. Join the online meeting.
In this Friday’s PCT Grand Rounds, Adrian Hernandez and Christopher Lindsell of Duke University will present “Virtual Vigilance: Monitoring of Decentralized Clinical Trials.” ” The Grand Rounds session will be held on Friday, February 23, 2024, at 1:00 pm eastern. Join the online meeting.
In this Friday’s PCT Grand Rounds, Adrian Hernandez and Christopher Lindsell of Duke University will present “Virtual Vigilance: Monitoring of Decentralized Clinical Trials.” ” The Grand Rounds session will be held on Friday, February 23, 2024, at 1:00 pm eastern. Join the online meeting.
Speakers Adrian Hernandez, MD Executive Director, Duke ClinicalResearch Institute Vice Dean, Duke University School of Medicine Christopher J. – How can we prepare research teams that do not always have the training and compensation to do all of these things?
Doctors and physicians rely on the results provided by a clinical scientist to make an accurate prognosis, diagnosis and assessment for a patient’s treatment plan. What is it Like to Work as a Clinical Scientist? A clinical scientist is often synonymous with: ClinicalResearch / Clinical Laboratory Scientist.
wearable device carried by patients to measure certain health-related parameters, remote patient monitoring) and tele-healthcare in clinical trials (e.g. data processing systems that support bioinformatics modelling) and digital record systems (e.g. video consultations), health data analytics (e.g. What comes next?
A notable issue with clinical trials is the homogeneity of the patient database. Dr. Charlie Kim earned his PhD from Microbiology and Immunology at Stanford University and pioneered the application of genomic and bioinformatic approaches to the study of infectious disease. About the interviewee.
Their work is driven by a profound understanding of disease biology and supported by advanced discovery platforms such as genetics and genomics, gene editing, bioinformatics, proteomics, bioengineering, image analysis, biobanks, disease-specific stem cell lines, and various animal models.
Recent advances in multi-omics approaches, including genomics, transcriptomics, proteomics, metabolomics, cytometry and imaging, in combination with bioinformatics and biostatistics, have been translated into several popular bioanalytical platforms, such as next-generation sequencing (NGS), single-cell analysis, flow cytometry and mass spectrometry.
The clinical trial landscape overall has evolved significantly with key changes in the social, ethical and regulatory environment globally with the creation of guidance by regulators with new regulatory pathways for approval of products specifically developed for diseases in LMIC and public health emergencies.
“There isn’t a member of the board of JLF who wouldn’t rather be able to do this without charging people,” said Andrew Jacobs, who sits on the boards of the foundation and NorRD Bio, a small Cambridge bioinformatics firm that helps make the vaccines. “It really was a choice of this or nothing.”
“Liquid biopsies have demonstrated promising activity in multiple clinical settings, but the great enthusiasm and expectations around them can be harmful if not adequately managed,” said Dr. El Mustapha Bahassi, PhD, Director, Clinical Laboratory Sciences, at the global clinicalresearch organization (CRO) Medpace.
study investigator and Professor of Clinical Neurology, University of California San Francisco (UCSF) Weill Institute for Neurosciences and clinicalresearch director, UCSF MS Center. Presentation Topic: Biomarkers and Bioinformatics. In the DAYBREAK trial, of 2,494 participants exposed to Zeposia for a total of 35.4
We organize all of the trending information in your field so you don't have to. Join 21,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content